Mereo BioPharma losses deepen on higher R&D spend

Writer, Stock Market Wire
Friday, March 23, 2018 - 07:55

Rare diseases pharmaceutical company Mereo BioPharma Group said annul losses deepened on the back of higher R&D spending.

Pre-tax losses amounted to £47.0m, compared to losses in the prior year of £33.7m.

'This has been a pivotal period for Mereo,' chief executive Denise Scots-Knight said.

'We announced positive top-line data with BCT-197 for AECOPD, our first significant clinical study read-out since the company's inception in mid-2015.

'Together with the positive BGS-649 data announced earlier this week, we have now successfully completed two substantial Phase 2 studies on our specialty pharma product candidates and initiated a Phase 2b study with BPS-804, our orphan disease product candidate for osteogenesis imperfecta in adults.'

'We also demonstrated the sustainability of our business model with the in-licensing of AZD-9668 from AstraZeneca for the rare disease Alpha-1 Antitrypsin Deficiency.'

'We continue to review a large number of opportunities to further diversify our portfolio, and look forward to reporting further significant progress and initiating additional clinical studies in 2018.'

Related content

Mereo BioPharma gets FDA fast-track designation for ovarian cancer treatment

Rare diseases focused Mereo BioPharma said it had been granted a fast-track designation by the US Food and Drug Administration for an ovarian cancer treatment....

Mon, 07/10/2019 - 13:10

Mereo BioPharma to present clinical trial data at Florida conference

Rare diseases focused Mereo BioPharma said data from a trial of its treatment for osteogenesis imperfecta would be presented at a key industry conference in...

Wed, 04/09/2019 - 13:19

Mereo BioPharma appoints Richard Francis as head of pharmaceutical development

Rare diseases focused Mereo BioPharma Group said it had appointed Richard Francis as its head of pharmaceutical development.

Francis was previously owner and senior director...

Tue, 16/07/2019 - 14:25

Mereo BioPharma meets with FDA to fast-track ovarian cancer treatment approval

Mereo BioPharma Group said it had held a successful meeting with the US Food and Drug Administration regarding a potential accelerated approval for navicixizumab for...

Mon, 15/07/2019 - 13:26

Mereo Biopharma AGM resolutions pass

Mereo BioPharma, a clinical stage biopharmaceutical company focused on rare diseases, announced all resolutions proposed at the Annual General Meeting, held yesterday, were duly passed....

Thu, 20/06/2019 - 09:25